Drug Trial Radar · NCT00084266
Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
Last checked: Nov 20, 2026Latest source record: Feb 1, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,225
Actual
Start
Oct 2004
Primary completion
Mar 2010
Study completion Mar 2010
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 11, 2004
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects. Subjects entered in to the study will have proven healthcare-associated methicillin-resistant Staphylococcus aureus pneumonia which will be treated with either linezolid or vancomycin.
Conditions
- Methicillin Resistant Staphylococcus Aureus (MRSA)
Interventions
linezolid (Zyvox)Drug
Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
vancomycinDrug
Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP PopulationTime frame: EOS (7-30 days after last dose)
Locations
177 sites in 22 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Huntsville, Alabama
Pfizer Investigational Site
Montgomery, Alabama
Pfizer Investigational Site
Montgomery, Alabama
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Orange, California
Pfizer Investigational Site
Redlands, California
Pfizer Investigational Site
Sacramento, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Francisco, California
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Newark, Delaware
Pfizer Investigational Site
Washington D.C., District of Columbia
Pfizer Investigational Site
Washington D.C., District of Columbia
Pfizer Investigational Site
Brandon, Florida
Pfizer Investigational Site
Fort Lauderdale, Florida
Pfizer Investigational Site
Gainesville, Florida
Pfizer Investigational Site
Jackson, Florida
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Orlando, Florida
Pfizer Investigational Site
Orlando, Florida
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
Augusta, Georgia
Pfizer Investigational Site
Augusta, Georgia
Pfizer Investigational Site
Decatur, Georgia
Pfizer Investigational Site
Decatur, Georgia
Pfizer Investigational Site
Honolulu, Hawaii
Pfizer Investigational Site
Chicago, Illinois
Pfizer Investigational Site
North Chicago, Illinois
Pfizer Investigational Site
Oak Park, Illinois
Pfizer Investigational Site
Springfield, Illinois
Pfizer Investigational Site
Springfield, Illinois
Pfizer Investigational Site
Springfield, Illinois
Showing 40 of 177 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.